Abstract 5α-Reductase type 2, the predominant prostatic isozyme of this protein, converts
testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater …

It has been suggested that the activity of the steroid 5α-reductase type II enzyme (encoded
by the SRD5A2 gene) may be associated with prostate cancer risk and that population …

Prostate cancer is a significant cause of death in Western countries and is under the strong
influence of androgens. The steroid 5α-reductase 2 catalyzes the metabolism of testosterone …

Several polymorphisms in the 5α-reductase type 2 (SRD5A2) gene have been implicated as
risk factors for prostate cancer. We performed a meta-analysis of 9 studies (12 comparisons) …

Controversy exists over the significance of associations between the SRD5A2 (5α‐
reductase type 2) polymorphisms, A49T and V89L, and risk of prostate cancer. These …

In the prostate, the enzyme encoded by the SRD5A2 gene (5α‐reductase) converts
testosterone to dihydrotestosterone, a potent androgen that has been hypothesized to play a …

Objectives. The valine (V) to leucine (L) polymorphism of the SRD5A2 gene is associated
with 5-alpha reductase-2 activity; patients with the V allele have high activity and patients …

OBJECTIVES:: To compare men with prostate disease with those from the general
population regarding polymorphisms in the androgen receptor gene and in the 5α-reductase …

BACKGROUND Increasing studies investigating the association between steroid 5‐alpha
reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to …

PURPOSE: The SRD5A2 gene codes the steroid 5-reductase type II, a critical mediator of
androgen action, and the V89L and A49T polymorphisms of this gene may be associated …